Biogen Inc (BIIB) Stock Price, Quote & News

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referenc...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 617 679 2000

Website: www.biogen.com

Address:

225 Binney Street, Cambridge, United States

Cad_Bane May. 22 at 6:12 PM

$BIIB failure after failure after failure. They laid off all foot troops but jept the same arrogant leadership - heads shoikd roll but rhey won’t because those DEI leaders will sue.

1 · Reply

MQuick May. 22 at 1:21 PM

$GANX time to invest in us $BIIB the first disease modiying drug for PD!

0 · Reply

notreload_ai May. 22 at 12:30 PM

$DNLI, $BIIB - Experimental Parkinson’s drug BIIB122 failed to slow disease in trials despite strong biological effects; development stopped. https://notreload.xyz/xy/biogen-denali-halt-biib122-after-parkinson-phase-2-failure/

0 · Reply

OpenOutcrier May. 22 at 12:30 PM

$BIIB (-1.0% pre) $DNLI (-3.1% pre) Biogen and Denali discontinue Parkinson's drug after trial fails https://ooc.bz/l/103323

0 · Reply

biotech May. 22 at 11:53 AM

$BIIB $DNLI Phase 2b LUMA study of BIIB122 in early-stage Parkinsons disease #did #not #meet its primary or secondary endpoints Biogen and Denali will #discontinue #development of BIIB122 in idiopathic Parkinsons disease $BIIB should return to $SGMO for #parkinson now w STAC-BBB

1 · Reply

mikesterz7 May. 22 at 3:09 AM

$BIIB $DNLI Biogen and Denali will stop further development of BIIB122 for the broader idiopathic form of Parkinson’s. Denali will continue its separate early-to-middle BEACON study of the same drug, but only in the smaller group of patients who carry a specific genetic mutation.

0 · Reply

StocktwitsNews May. 21 at 11:03 PM

BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial $BIIB $DNLI https://stocktwits.com/news/equity/markets/biib-dnli-stocks-edge-lower-after-hours-parkinsons-drug-misses-key-goals-in-trial/cZXCkReRe8V

0 · Reply

CapitalMonk May. 21 at 9:03 PM

$BIIB Price: $189.47 (+0.89%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.69% RSI: 53.1 | Momentum: Moderate Volume: +20.4% vs avg Volatility: 2.46% Support: $179.15 | Resistance: $205.97 Sourch: http://marketbaubles.com/

0 · Reply

LuckEtradER May. 20 at 1:13 PM

$BIIB retatrutide peptide gonna be huge. 2027 approval likely. 👀

0 · Reply

BullDonald May. 19 at 7:38 PM

$BIIB When you guys are anticipating LUMA pahase 2/B data. at this point m complilty has no clue about it. says Mid 2026 ! Any HINT any one got about how the data looks like ?

0 · Reply

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

May 21, 2026, 6:17 PM EDT - 2 days ago

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study

2026-05-21T22:05:12.000Z - 2 days ago

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

DNLI

May 21, 2026, 6:00 PM EDT - 2 days ago

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease

2026-05-15T12:57:10.000Z - 8 days ago

Biogen resumed with an Outperform at Evercore ISI

2026-05-15T10:43:43.000Z - 8 days ago

Biogen price target raised to $225 from $214 at Piper Sandler

May 14, 2026, 7:10 PM EDT - 9 days ago

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

2026-05-14T19:18:29.000Z - 9 days ago

Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright

ALEC DNLI DYN PRTA

May 14, 2026, 12:10 PM EDT - 9 days ago

Biogen advances Alzheimer's drug to late-stage trial despite disappointing data

2026-05-14T14:52:34.000Z - 9 days ago

Biogen completes acquisition of Apellis Pharmaceuticals

APLS

2026-05-14T13:22:53.000Z - 9 days ago

Biogen’s diranersen shows benefits in early Alzheimer’s Disease

IONS

2026-05-14T13:08:49.000Z - 9 days ago

Ionis announces Biogen’s CELIA study did not meet primary endpoint

IONS

May 14, 2026, 9:07 AM EDT - 9 days ago

Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.

May 14, 2026, 8:35 AM EDT - 9 days ago

Biogen Completes Acquisition of Apellis Pharmaceuticals

2026-05-14T12:34:20.000Z - 9 days ago

Biogen up 8% at $220 after Phase 2 diranersen data in Alzheimer’s Disease

May 14, 2026, 7:03 AM EDT - 9 days ago

Biogen's Alzheimer's drug fails to meet mid-stage trial goal

May 14, 2026, 6:59 AM EDT - 9 days ago

Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease

May 13, 2026, 2:20 PM EDT - 10 days ago

Biogen Transcript: Bank of America Global Healthcare Conference 2026

2026-05-08T09:20:59.000Z - 16 days ago

Eisai, Biogen announce FDA extension of review period for lecanemab-irmb sBLA

May 8, 2026, 2:30 AM EDT - 16 days ago

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

2026-05-07T22:27:46.000Z - 16 days ago

Remitly Global to replace Apellis in S&P 600 at open on 5/14

APLS RELY

May 7, 2026, 6:01 PM EDT - 16 days ago

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

APLS BFAM RELY TPH

May 7, 2026, 4:01 PM EDT - 16 days ago

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

STOK

2026-05-01T14:53:17.000Z - 22 days ago

Biogen upgraded to Buy from Hold at Freedom Broker

2026-05-01T12:48:48.000Z - 22 days ago

Biogen price target raised to $190 from $189 at Truist

2026-05-01T10:17:29.000Z - 22 days ago

Biogen price target raised to $200 from $190 at Citi

2026-04-30T17:54:40.000Z - 23 days ago

Biogen price target raised to $206 from $200 at Morgan Stanley

2026-04-30T14:06:05.000Z - 23 days ago

Biogen price target raised to $222 from $213 at RBC Capital

2026-04-30T11:55:25.000Z - 23 days ago

Biogen price target raised to $196 from $191 at Wedbush

Apr 29, 2026, 8:00 AM EDT - 24 days ago

Biogen Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 24 days ago

Biogen Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 24 days ago

Biogen Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 24 days ago

Biogen Quarterly report: Q1 2026

Apr 29, 2026, 7:02 AM EDT - 24 days ago

Biogen Lowers 2026 Earnings Outlook

Apr 29, 2026, 6:07 AM EDT - 24 days ago

Biogen cuts annual profit forecast on acquisition-related charges

Apr 28, 2026, 8:00 AM EDT - 25 days ago

Biogen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 25 days ago

Biogen Proxy statement: Proxy filing

Apr 20, 2026, 9:02 AM EDT - 4 weeks ago

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma

Apr 20, 2026, 7:30 AM EDT - 4 weeks ago

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

Apr 18, 2026, 9:00 AM EDT - 5 weeks ago

These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

LLY

Apr 7, 2026, 6:00 AM EDT - 6 weeks ago

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform

Mar 31, 2026, 9:41 AM EDT - 7 weeks ago

Why This Pharma Stock More Than Doubled Today

APLS

Mar 31, 2026, 8:30 AM EDT - 7 weeks ago

Biogen Transcript: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 7 weeks ago

Biogen Press release: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 7 weeks ago

Biogen Slides: M&A announcement

Mar 31, 2026, 8:07 AM EDT - 7 weeks ago

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases

APLS

Mar 31, 2026, 7:44 AM EDT - 7 weeks ago

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

APLS

Mar 31, 2026, 7:05 AM EDT - 7 weeks ago

Biogen to buy Apellis Pharmaceuticals for $5.6 billion

APLS

Mar 31, 2026, 6:59 AM EDT - 7 weeks ago

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.

APLS

Mar 31, 2026, 6:59 AM EDT - 7 weeks ago

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

APLS

Mar 30, 2026, 7:36 AM EDT - 7 weeks ago

US FDA approves higher-dose of Biogen's genetic disorder drug

Mar 30, 2026, 7:30 AM EDT - 7 weeks ago

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

IONS

Mar 28, 2026, 3:00 PM EDT - 2 months ago

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Mar 20, 2026, 12:05 PM EDT - 2 months ago

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Mar 19, 2026, 7:30 AM EDT - 2 months ago

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Mar 18, 2026, 9:30 AM EDT - 2 months ago

Biogen Transcript: Stifel 2026 Virtual CNS Forum

Mar 11, 2026, 8:00 AM EDT - 2 months ago

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Mar 10, 2026, 1:00 PM EDT - 2 months ago

Biogen Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 7:30 AM EST - 2 months ago

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

IONS

Mar 4, 2026, 5:06 PM EST - 2 months ago

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

STOK

Mar 2, 2026, 9:10 AM EST - 2 months ago

Biogen Transcript: TD Cowen 46th Annual Health Care Conference

Feb 13, 2026, 10:30 AM EST - 3 months ago

Biogen Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 11, 2026, 5:00 PM EST - 3 months ago

Biogen Announces Board Chair Transition

Feb 6, 2026, 8:59 AM EST - 3 months ago

Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide

Feb 6, 2026, 8:30 AM EST - 3 months ago

Biogen Earnings Call Transcript: Q4 2025

Feb 6, 2026, 8:30 AM EST - 3 months ago

Biogen Annual report: Q4 2025

Feb 6, 2026, 8:30 AM EST - 3 months ago

Biogen Earnings release: Q4 2025

Feb 6, 2026, 8:30 AM EST - 3 months ago

Biogen Slides: Q4 2025

Feb 6, 2026, 7:35 AM EST - 3 months ago

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.

Feb 6, 2026, 6:10 AM EST - 3 months ago

Biogen forecasts annual profit above estimates as Leqembi sales pick up

Feb 4, 2026, 7:30 AM EST - 3 months ago

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Jan 28, 2026, 7:30 AM EST - 4 months ago

Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Jan 25, 2026, 6:30 PM EST - 4 months ago

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

Jan 20, 2026, 8:29 AM EST - 4 months ago

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

LLY VKTX

Cad_Bane May. 22 at 6:12 PM

$BIIB failure after failure after failure. They laid off all foot troops but jept the same arrogant leadership - heads shoikd roll but rhey won’t because those DEI leaders will sue.

1 · Reply

MQuick May. 22 at 1:21 PM

$GANX time to invest in us $BIIB the first disease modiying drug for PD!

0 · Reply

notreload_ai May. 22 at 12:30 PM

0 · Reply

OpenOutcrier May. 22 at 12:30 PM

$BIIB (-1.0% pre) $DNLI (-3.1% pre) Biogen and Denali discontinue Parkinson's drug after trial fails https://ooc.bz/l/103323

0 · Reply

biotech May. 22 at 11:53 AM

1 · Reply

mikesterz7 May. 22 at 3:09 AM

0 · Reply

StocktwitsNews May. 21 at 11:03 PM

0 · Reply

CapitalMonk May. 21 at 9:03 PM

0 · Reply

LuckEtradER May. 20 at 1:13 PM

$BIIB retatrutide peptide gonna be huge. 2027 approval likely. 👀

0 · Reply

BullDonald May. 19 at 7:38 PM

$BIIB When you guys are anticipating LUMA pahase 2/B data. at this point m complilty has no clue about it. says Mid 2026 ! Any HINT any one got about how the data looks like ?

0 · Reply

jewell69 May. 19 at 7:16 PM

$BIIB ancient history of trades 03/19/2025 Sell BIIB BIOGEN INC 25 $142.20 $0.10 $3,554.90 More 03/12/2025 Buy BIIB BIOGEN INC 25 $140.70 -$3,517.50 5/19/26 b just now 10 3:13 pm edt 191.94 I guess I should have bought and held

0 · Reply

JFais May. 15 at 3:11 PM

$BIIB completes $APLS acquisition ... next neph target to go?

0 · Reply

Quantumup May. 15 at 10:23 AM

Citizens reiterated $LRMR Market Outperform; $18 $BIIB SLDB PTCT NBIX - VYGR DSGN $LXEO Here's what Citizens said in its note to investors: https://x.com/Quantumup1/status/2055231979113591296?s=20

0 · Reply

MarketBeat May. 14 at 11:11 PM

https://marketbeat.com/a/8655098/ $BIIB Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

1 · Reply

topstockalerts May. 14 at 4:24 PM

“We’re really excited that we’ve been able to demonstrate an unprecedented combination of tau reduction in pathology and the cognitive benefit and have been really getting close to isolating a dose,” she said. “Those are the three requirements you need to go to Phase 3.” The results mark the latest example of Biogen’s uneven journey to develop drugs for Alzheimer’s. Biogen for years has been researching the brain disease. It’s brought two drugs to market designed to slow cognitive decline, though it pulled its first drug, Aduhelm, after it couldn’t overcome controversy surrounding its approval. Both Aduhelm and Biogen’s other Alzheimer’s drug Leqembi remove a protein associated with Alzheimer’s called amyloid from the brain. Its latest experimental drug Diranersen is an antisense oligonucleotide that limits production of another protein called tau. Rival Eli Lilly is also studying drugs that seek to decrease levels of tau. $BIIB $LLY

0 · Reply

topstockalerts May. 14 at 4:24 PM

Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. Nonetheless, Biogen plans to move it into Phase 3 testing because of signals suggesting the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest dose. Dr. Priya Singhal, Biogen’s head of development, said the results are compelling. $BIIB

0 · Reply

EPR53167 May. 14 at 2:48 PM

$BIIB Loaded up on May and Jun calls on $194 print from $215+ premarket…

0 · Reply

Cad_Bane May. 14 at 2:13 PM

$BIIB this company is s steeped in DEI that they even promote drugs that are not worthy🤣🤣🤣🤣

0 · Reply

biotech May. 14 at 2:11 PM

$BIIB + $SGMO TAU partnership is now $SGMO + Roche Partnership Tau target is now confirmed Roche received approval for a procedure in diagnosis of ALZ May 11 #Elecsys® pTau217 first blood test Alzheimer’s lets see if $SGMO got a milestone payment from Roche tonight MIZUHO The interesting piece here though $BIIB is moving TAU forward "based on the strength of the biomarker and efficacy data" low dose of 60mg every 24 weeks seemed to have most profound effect on the pre-specified cognitive measures...

1 · Reply

Kaltycoon May. 14 at 1:55 PM

$NMRA all right $BIIB we see you, we got our own stuff developing. Some validation if they believe they can advance the trial despite setbacks. https://investors.biogen.com/news-releases/news-release-details/topline-results-phase-2-celia-study-diranersen-biib080-first

0 · Reply

mikesterz7 May. 14 at 1:09 PM

$BIIB 🔥🔥🔥 Biogen said the overall biomarker and efficacy data were strong enough to advance the drug into registrational development, even though the trial did not meet the primary endpoint. The 18-month placebo-controlled study showed strong reductions in tau levels across all doses tested.

0 · Reply

DonCorleone77 May. 14 at 1:05 PM

$BIIB $NVDA $DOCS $ENVX $BLSH PRE-MARKET MOVERS: Currently Higher After Earnings: - StubHub (STUB) up 14.1% - Cisco (CSCO) up 15.6% - Klarna (KLAR) up 15.2% - Yeti (YETI) up 7.7% - Viking Holdings (VIK) up 6.3% Currently Also Higher: - Biogen (BIIB) up 1.7% after reporting topline results from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide therapy targeting tau, in individuals with early Alzheimer's disease - Nvidia (NVDA) up 1.7% after Reuters reported the U.S. has approved about 10 Chinese companies to purchase Nvidia H200 chips Currently Lower After Earnings: - Doximity (DOCS) down 20.0% - Enovix (ENVX) down 12.3% - Bullish (BLSH) down 7.0%.

0 · Reply

Market Cap	28.61B
Revenue (ttm)	9.89B
Net Income (ttm)	1.29B
EPS (ttm)	N/A
PE Ratio	11.96
Forward PE	13.36
Profit Margin	13.07%
Debt to Equity Ratio	0.34

Volume	892,900
Avg Vol	1,219,894
Day's Range	N/A - N/A
Shares Out	147.64M
Stochastic %K	39%
Beta	0.19
Analysts	Strong Sell
Price Target	$218.97